PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
Phase 4
Terminated
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Insulin lispro (Humalog)Drug: Inhaled Human Insulin (Exubera®)
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 58
- Registration Number
- NCT00356421
- Locations
- 🇬🇧
Pfizer Investigational Site, Birmingham, West Midlands, United Kingdom
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension
Phase 3
Completed
- Conditions
- HypertensionBlood Pressure, High
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00355589
- Locations
- 🇺🇸
Lovelace Scientific Resources, Sarasota, Florida, United States
🇺🇸Partners in Primary Care, Voorhees, New Jersey, United States
🇺🇸Medford Medical Clinic Research Dept., Medford, Oregon, United States
[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.
Phase 2
Terminated
- Conditions
- Pain
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2007-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00354094
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.
Phase 2
Terminated
- Conditions
- Pain
- Interventions
- Drug: [S,S]-Reboxetine
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 112
- Registration Number
- NCT00353808
- Locations
- 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States
A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061
Phase 2
Completed
- Conditions
- HIV-1
- Interventions
- Drug: UK-453,061
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2013-10-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 49
- Registration Number
- NCT00348673
- Locations
- 🇩🇪
Pfizer Investigational Site, Koeln, Germany
[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.
Phase 2
Terminated
- Conditions
- Pain
- Interventions
- Drug: [S,S]-ReboxetineDrug: Any
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 136
- Registration Number
- NCT00348894
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 191
- Registration Number
- NCT00348374
- Locations
- 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico
Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy
Phase 4
Terminated
- Conditions
- Pain, Postoperative
- Interventions
- Drug: Morphine, Placebo
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2011-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT00346268
- Locations
- 🇩🇪
Pfizer Investigational Site, Reutlingen, Germany
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00338884
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
[S,S]-Reboxetine Add-On Trial
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 136
- Registration Number
- NCT00334685
- Locations
- 🇬🇧
Pfizer Investigational Site, York, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath